Results 191 to 198 of about 7,028 (198)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

Journal of Clinical Pharmacology, 2019
Mohamed-Eslam F Mohamed, Tian Feng, Thomas Marbury   +2 more
exaly  

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Lancet, The, 2019
Josef S Smolen, Aileen L Pangan, Paul Emery   +2 more
exaly  

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Lancet, The, 2019
Desirée Van Der Heijde, In-Ho Song, Aileen L Pangan   +2 more
exaly  

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

British Journal of Clinical Pharmacology, 2017
Mohamed-Eslam F Mohamed, Ahmed A Othman
exaly  

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

AAPS Journal, 2019
Mohamed-Eslam F Mohamed, Ahmed A Othman, Patrick Marroum   +2 more
exaly  

Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies

International Immunopharmacology
Huijuan Wang, Yu-Hong Huang, Cong Dai
exaly  

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Lancet, The, 2018
Mark C Genovese, Roy Fleischmann, Bernard Combe   +2 more
exaly  

Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study

International Immunopharmacology
Jiaoquan Chen, Rujun Xue, Aili Gao
exaly